Immunomodulatory treatment in postural tachycardia syndrome: A case series

Postural tachycardia syndrome (POTS) is a form of autonomic dysfunction characterized by symptoms of orthostatic intolerance, often accompanied by sudomotor dysfunction and gastrointestinal dysmotility. Recently, evidence has accumulated that in a subset of patients, the pathogenesis of dysautonomia may be immune‐mediated. The aim of the current report was to evaluate the use of intravenous immunoglobulin (IVIG) treatment in patients with progressive and/or refractory immune‐mediated POTS.

[1]  M. Persson,et al.  Serum Activity Against G Protein–Coupled Receptors and Severity of Orthostatic Symptoms in Postural Orthostatic Tachycardia Syndrome , 2020, Journal of the American Heart Association.

[2]  S. Raj,et al.  Canadian Cardiovascular Society Position Statement on Postural Orthostatic Tachycardia Syndrome (POTS) and Related Disorders of Chronic Orthostatic Intolerance. , 2020, Canadian Journal of Cardiology.

[3]  J. Schofield,et al.  Intravenous Immunoglobulin Therapy in Refractory Autoimmune Dysautonomias: A Retrospective Analysis of 38 Patients. , 2019, American journal of therapeutics.

[4]  J. Schofield,et al.  How We Treat Autoimmune Small Fiber Polyneuropathy with Immunoglobulin Therapy , 2019, European Neurology.

[5]  R. Treister,et al.  IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety , 2018, Therapeutic advances in neurological disorders.

[6]  B. Grubb,et al.  The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review , 2017, Scandinavian cardiovascular journal : SCJ.

[7]  O. Melander,et al.  Antiadrenergic autoimmunity in postural tachycardia syndrome , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[8]  Hongliang Li,et al.  Autoimmune Basis for Postural Tachycardia Syndrome , 2014, Journal of the American Heart Association.

[9]  G. Sobue,et al.  The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[10]  G. Sobue,et al.  The spectrum of clinicopathological features in pure autonomic neuropathy , 2012, Journal of Neurology.

[11]  Jens Jordan,et al.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome , 2011, Clinical Autonomic Research.

[12]  P. Sandroni,et al.  Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy , 2009, Neurology.

[13]  P. Sandroni,et al.  Other autonomic neuropathies associated with ganglionic antibody , 2009, Autonomic Neuroscience.

[14]  P. Sandroni,et al.  Autonomic Ganglia: Target and Novel Therapeutic Tool , 2009 .

[15]  W. Shen,et al.  Postural orthostatic tachycardia syndrome: the Mayo clinic experience. , 2007, Mayo Clinic proceedings.